MétaCan
Menu
Back to cohort
Record W4415470278 · doi:10.1111/jvh.70098

Hepatitis B Virus ( <scp>HBV</scp> ) Treatment Eligibility in the <scp>UK</scp> : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines

2025· article· en· W4415470278 on OpenAlexaff
Cori Campbell, Tingyan Wang, Alexander Stockdale, Stacy Todd, J Jaworski, Ben Glampson, Dimitri Papadimitriou, Erik Mayer, Hizni Salih, Gail Roadknight, Stephanie Little, Theresa Noble, Kinga A. Várnai, Cai Davis, Ashley Heinson, Michael George, Florina Borca, Timothy K. Roberts, Baptiste Briot Ribeyre, Louise English, Leilei Zhu, Kerrie Woods, Jim Davies, Graham Cooke, Eleni Nastouli, Salim I. Khakoo, William Gelson, Ahmed M. Elsharkawy, Eleanor Barnes, Philippa C. Matthews

Bibliographic record

VenueJournal of Viral Hepatitis · 2025
Typearticle
Languageen
FieldMedicine
TopicHepatitis B Virus Studies
Canadian institutionsInstitute of Infection and Immunity
FundersUniversity College London Hospitals NHS Foundation TrustUniversity College LondonDepartment of Health and Social CareNational Institute for Health and Care ResearchFrancis Crick InstituteHome Instead Charities
KeywordsMedical prescriptionHepatitis B virusPopulationCohortRetrospective cohort studyHepatitis BLiver diseaseViral loadChronic hepatitisHepatitis C

Abstract

fetched live from OpenAlex

Nucleos/tide analogue (NA) drugs are used for long-term treatment of chronic hepatitis B virus (HBV) infection, with treatment eligibility criteria changing rapidly amidst globally evolving clinical guidelines. We aimed to quantify the prescription of NA drugs to date, and to undertake a preliminary assessment of the impact of relaxing treatment eligibility thresholds, leveraging a unique large real-world secondary care dataset. We assimilated longitudinal clinical data, collected between February 1997 and April 2023 from adults with chronic HBV infection from six centres in England through the UK NIHR Health Informatics Collaborative (HIC) Viral Hepatitis and Liver Disease theme. We describe factors currently associated with the receipt of NA treatment and determine the proportion of the population who would become treatment eligible as thresholds change. Across 7558 adults with a mean follow-up of 4.0 years (SD 3.9), NA treatment was prescribed in 2014/7558 (26.6%), and as expected according to guidelines at the time, was associated with HBV e-antigen (HBeAg) positivity and alanine transferase (ALT) above the upper limit of normal (> ULN). Treatment was more likely in males, older adults, in Asian and Other ethnicities (compared to White), and less likely in socioeconomically deprived individuals. The proportion of treatment-eligible individuals was 32.3% based on 2 records of ALT > ULN over 6-12 months, 41.7% based on ALT > ULN and viral load (VL) > 2000 IU/mL, and 95.1% based on detectable VL and either ALT > ULN or age > 30 years. Evolving clinical guidelines will lead to substantial increases in the proportion of individuals living with HBV who are eligible for treatment, underlining the need for services to adapt rapidly to the changing clinical environment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.015
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.156
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0050.015
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.168
GPT teacher head0.459
Teacher spread0.291 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Viral HepatitisSame topicHepatitis B Virus StudiesFrench-language works237,207